← Human Trials & Peer-Reviewed Studies
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Plain-language guide to PMID 19853906 (2009): double-blind randomized controlled trial study of Liraglutide in 564 individuals.
Key Facts
- PMID
- 19853906
- Journal
- Lancet (London, England)
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Astrup A et al. (9 authors)
- DOI
- 10.1016/S0140-6736(09)61375-1
- Registered trial
- NCT04529278, NCT00422058
What This Study Did, in Plain Language
What Was Tested
Researchers studied Liraglutide in this randomized controlled trial publication.
The researchers assessed the effect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes.
Who Took Part
The abstract describes 564 individuals taking part.
PubMed tags the participants as both men and women.
How the Study Was Run
The design is described as randomized, double-blind, open-label and placebo-controlled.
The individuals were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
Neither the individuals nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.
Everyone knew when Liraglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.
Weight change analysed by intention to treat was the primary endpoint.
An 84-week open-label extension followed.
This study is registered with ClinicalTrials.gov, number NCT00422058.
What Was Measured
The researchers assessed the effect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes.
The subject headings attached to it are Analysis of Variance, Anti-Obesity Agents, Body Mass Index, Europe, Glucagon-Like Peptide 1, Lactones and Liraglutide.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Liraglutide in 564 individuals.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2009 (Lancet (London, England)), a journal based in England.
More context: the Liraglutide compound page.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.